Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
复制标题
DOI：
10.1001/jamadermatol.2015.1916
复制
发表时间：
2015-11
期刊：
影响因子：
10.9
通讯作者：
Ortiz-Urda, Susana
中科院分区：
文献类型：
--
作者：
Sanlorenzo, Martina;Vujic, Igor;Daud, Adil;Algazi, Alain;Gubens, Matthew;Luna, Sara Alcantara;Lin, Kevin;Quaglino, Pietro;Rappersberger, Klemens;Ortiz-Urda, Susana
免疫调节抗癌药物，如抗程序性死亡-1药物pembrolizumab，在试验中显示出良好的效果，将有更多的患者接受此类治疗。关于这些药物引起的皮肤不良事件(AEs)及其与治疗反应的可能相关性，人们知之甚少。描述培溴利珠单抗引起的皮肤不良反应的频率和频谱及其与治疗反应的可能相关性。对2011年3月1日至2014年5月28日期间接受培溴利珠单抗治疗的癌症患者进行了一项单一机构的回顾性病历审查。这项综述包括83名连续的患者，他们参加了2项临床试验，接受了至少1剂培溴利珠单抗，并进行了至少1次随访。按培溴利珠单抗治疗方案分组：43例每3周服用10 mg/kg，24例每2周服用10 mg/kg，16例每3周服用2 mg/kg。66例黑色素瘤患者，15例肺癌患者，1例前列腺癌患者，1例默克尔细胞癌患者。中位随访时间为15周(范围2-105周)。该分析是在2014年3月1日至9月30日进行的。皮肤不良反应的发生、严重程度和类型，以及疾病进展和对培溴利珠单抗治疗的反应。35名患者(42%)出现了可归因于培溴利珠单抗的皮肤不良反应。最常见的皮肤不良反应是黄斑丘疹(24例(29%))、瘙痒(10例(12%))和色素减退(7例(8%))。所有7名出现色素减退的患者都接受了黑色素瘤的治疗。生存分析表明，与未发生皮肤AEs的患者相比，发生皮肤AEs的所有3组患者(Pembrolizumab，10 mg/kg，每3周，P=.001；Pembrolizumab，10 mg/kg，每2周，P=.003；Pembrolizumab，2 mg/kg，每3周，P=.009)的无进展间隔都明显长于未发生皮肤AEs的患者。在42%的患者中，培溴利珠单抗治疗与皮肤不良反应有关。皮肤AEs的发展，特别是黑色素瘤患者的色素减退，可能会导致更好的治疗反应。
Immunomodulatory anticancer drugs, such as the anti–programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs and their possible correlation with treatment response. To describe the frequency and spectrum of cutaneous AEs linked with pembrolizumab and their possible correlation with treatment response. A single-institution, retrospective medical record review was conducted of patients with cancer who were treated with pembrolizumab from March 1, 2011, to May 28, 2014. The review comprised 83 consecutive patients who were enrolled in 2 clinical trials, received at least 1 dose of pembrolizumab, and had at least 1 follow-up visit. Patients were grouped according to the following therapeutic regimen for pembrolizumab: 43 received 10 mg/kg every 3 weeks, 24 received 10 mg/kg every 2 weeks, and 16 received 2 mg/kg every 3 weeks. Sixty-six patients were treated for melanoma, 15 patients for lung cancer, 1 patient for prostate cancer, and 1 patient for Merkel cell carcinoma. Median follow-up was 15 weeks (range, 2-105 weeks). The analysis was conducted from March 1 to September 30, 2014. Occurrence, severity, and type of cutaneous AEs, as well as disease progression and response to pembrolizumab treatment. Thirty-five patients (42%) developed cutaneous AEs attributed to pembrolizumab. The most common cutaneous AEs were macular papular eruption (24 [29%]), pruritus (10 [12%]), and hypopigmentation (7 [8%]). All 7 patients who developed hypopigmentation were treated for melanoma. Survival analyses showed that patients who developed cutaneous AEs had significantly longer progression-free intervals in all 3 groups (pembrolizumab, 10 mg/kg, every 3 weeks, P = .001; pembrolizumab, 10 mg/kg, every 2 weeks, P = .003; pembrolizumab, 2 mg/kg, every 3 weeks, P = .009) compared with patients who did not develop cutaneous AEs. Pembrolizumab therapy was associated with cutaneous AEs in 42% of patients. The development of cutaneous AEs, especially of hypopigmentation in patients with melanoma, could point toward better treatment response.
登录
查看更多内容
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
影响因子：
50.5
作者：
Quaglino, P.;Marenco, F.;Bernengo, M. G.
通讯作者：
Bernengo, M. G.
DOI：
10.1016/s0190-9622(83)70182-9
发表时间：
1983-01-01
影响因子：
13.8
作者：
NORDLUND, JJ;KIRKWOOD, JM;LERNER, AB
通讯作者：
LERNER, AB
影响因子：
3.7
作者：
Voskens CJ;Goldinger SM;Loquai C;Robert C;Kaehler KC;Berking C;Bergmann T;Bockmeyer CL;Eigentler T;Fluck M;Garbe C;Gutzmer R;Grabbe S;Hauschild A;Hein R;Hundorfean G;Justich A;Keller U;Klein C;Mateus C;Mohr P;Paetzold S;Satzger I;Schadendorf D;Schlaeppi M;Schuler G;Schuler-Thurner B;Trefzer U;Ulrich J;Vaubel J;von Moos R;Weder P;Wilhelm T;Göppner D;Dummer R;Heinzerling LM
通讯作者：
Heinzerling LM
DOI：
10.1056/nejmoa1305133
发表时间：
2013-07-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hamid O;Robert C;Daud A;Hodi FS;Hwu WJ;Kefford R;Wolchok JD;Hersey P;Joseph RW;Weber JS;Dronca R;Gangadhar TC;Patnaik A;Zarour H;Joshua AM;Gergich K;Elassaiss-Schaap J;Algazi A;Mateus C;Boasberg P;Tumeh PC;Chmielowski B;Ebbinghaus SW;Li XN;Kang SP;Ribas A
通讯作者：
Ribas A